GlassScriptPhysician profile
George Apostolides
NPI 1972570158
$15,445.71
in general payments reported to CMS, 2019-2025
21 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,359 · 2020: $192 · 2021: $1,901 · 2022: $1,336 · 2023: $3,040 · 2024: $2,374 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,696 · Travel and Lodging: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,696.23 |
| Travel and Lodging | $1,961.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $2,420.84 | 2019-2025 | Phasix Mesh |
| Pacira Pharmaceuticals Incorporated | $2,194.82 | 2019 | |
| Axonics, INC. | $1,924.03 | 2020-2024 | Axonics |
| W. L. Gore & Associates, INC. | $1,630.33 | 2023-2025 | Gore Bio-A Tissue Reinforcement, Gore Synecor Preperitoneal Biomaterial |
| Intuitive Surgical, INC. | $1,366.95 | 2022-2024 | |
| Applied Medical Resources Corporation | $1,033.33 | 2019 | |
| Stryker Corporation | $950.02 | 2019-2025 | 1788, Spy-Phi System |
| Ethicon US, LLC | $919.50 | 2019-2025 | Stratafix, Enseal X1, Enseal |
| C. R. Bard, INC. & Subsidiaries | $628.92 | 2019 | |
| Becton, Dickinson and Company | $560.38 | 2019-2025 | Phasix Mesh |
| Integra Lifesciences Corporation | $511.79 | 2022-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Allergan, INC. | $392.48 | 2019-2022 | |
| Thd America, INC. | $245.70 | 2022-2023 | |
| Braintree Laboratories, INC. | $142.58 | 2021-2024 | Sutab, Suflave |
| Tela Bio, INC. | $140.09 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $136.13 | 2019 | |
| Medtronic USA, INC. | $116.69 | 2019 | |
| Ferring Pharmaceuticals INC. | $40.41 | 2019-2024 | Rebyota |
| Boston Scientific Corporation | $37.10 | 2020-2025 | Axonics |
| Takeda Pharmaceuticals U.S.A., INC. | $36.42 | 2021-2023 | Entyvio |
| Abbvie INC. | $17.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Apostolides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.